Figure 6
Figure 6. Types and prognostic impact of new lesions found in patients with noninformative or normal MC. (A) The percentage of patients with normal or noninformative MC in whom new chromosomal lesions were found by SNP-A (left). Type and location of abnormalities are displayed in Table S1 and Figure 4. Stars mark the patients with sAML and noninformative MC in whom IPSS risk category cannot be determined. (B) Kaplan-Meier analysis of survival of patients (irrespective of the treatment received) with normal MC in whom new defects were identified using SNP-A as compared with these with a normal karyotype as evidenced by both negative SNP-A and MC. (C) Survival curves of sAML patients with normal SNP-A result versus patients with abnormal MC and those with normal MC in whom new lesions were found by SNP-A (left). Survival of sAML patients grouped into those with and without additional defects identified by SNP-A (right). (D) Survival curves of patients with MDS/MPD subgrouped into those with normal SNP-A, normal MC, but additional lesions by SNP-A, and patients with abnormal MC results. (E) Survival curves of patients with MDS and IPSS int-1 subgrouped based on the presence or absence of new lesions found by SNP-A irrespective of the MC result.

Types and prognostic impact of new lesions found in patients with noninformative or normal MC. (A) The percentage of patients with normal or noninformative MC in whom new chromosomal lesions were found by SNP-A (left). Type and location of abnormalities are displayed in Table S1 and Figure 4. Stars mark the patients with sAML and noninformative MC in whom IPSS risk category cannot be determined. (B) Kaplan-Meier analysis of survival of patients (irrespective of the treatment received) with normal MC in whom new defects were identified using SNP-A as compared with these with a normal karyotype as evidenced by both negative SNP-A and MC. (C) Survival curves of sAML patients with normal SNP-A result versus patients with abnormal MC and those with normal MC in whom new lesions were found by SNP-A (left). Survival of sAML patients grouped into those with and without additional defects identified by SNP-A (right). (D) Survival curves of patients with MDS/MPD subgrouped into those with normal SNP-A, normal MC, but additional lesions by SNP-A, and patients with abnormal MC results. (E) Survival curves of patients with MDS and IPSS int-1 subgrouped based on the presence or absence of new lesions found by SNP-A irrespective of the MC result.

Close Modal

or Create an Account

Close Modal
Close Modal